A Placebo Controlled, Double-blind, Randomised Trial Investigating Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics After Intravenous Administration of FE 204205 in Patients With Cirrhotic Portal Hypertension
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs FE 204205 (Primary)
- Indications Portal hypertension
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 11 Oct 2017 Status changed from recruiting to discontinued due to difficulty in recruitment
- 07 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Feb 2018.
- 07 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2018.